Matthias
Drosten
Publicaciones (44) Publicaciones de Matthias Drosten
2024
-
A new BRAF inhibitor breaks resistance barriers
Trends in Cancer
2023
-
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
The Journal of clinical investigation, Vol. 133, Núm. 7
-
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Nature Communications, Vol. 14, Núm. 1
2022
-
KRAS inhibitors: going noncovalent
Molecular Oncology
-
KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors
Molecular Oncology, Vol. 16, Núm. 17, pp. 3066-3081
-
Targeting KRAS mutant lung cancer: light at the end of the tunnel
Molecular Oncology, Vol. 16, Núm. 5, pp. 1057-1071
2021
-
KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform
Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 30
-
RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression
Cancer Cell
-
RASless MEFs as a Tool to Study RAS-Dependent and RAS-Independent Functions
Methods in Molecular Biology (Humana Press Inc.), pp. 335-346
2020
-
Requirement for epithelial p38α in KRAS-driven lung tumor progression
Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 5, pp. 2588-2596
-
Targeting the MAPK Pathway in KRAS-Driven Tumors
Cancer Cell, Vol. 37, Núm. 4, pp. 543-550
-
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas
Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 39, pp. 24415-24426
2019
-
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF
Cancer Cell, Vol. 35, Núm. 4, pp. 573-587.e6
2018
-
Allele-specific mechanisms of activation of mek1 mutants determine their properties
Cancer Discovery, Vol. 8, Núm. 5, pp. 648-661
-
ERF deletion rescues RAS deficiency in mouse embryonic stem cells
Genes and Development, Vol. 32, Núm. 7-8, pp. 568-576
-
Genetically engineered mouse models of K-Ras-driven lung and pancreatic tumors: Validation of therapeutic targets
Cold Spring Harbor Perspectives in Medicine, Vol. 8, Núm. 5
-
The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer
Cell Cycle, Vol. 17, Núm. 6, pp. 702-711
-
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling
Cancer Cell, Vol. 33, Núm. 2, pp. 217-228.e4
2017
-
A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer
PLoS Genetics, Vol. 13, Núm. 3
-
Clasp2 ensures mitotic fidelity and prevents differentiation of epidermal keratinocytes
Journal of Cell Science, Vol. 130, Núm. 4, pp. 683-688